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Isolation of genes encoding the receptors for steroids, retinoids, vitamin D, and thyroid hormone
and their structural and functional analysis revealed an evolutionarily conserved template for nu-
clear hormone receptors. This discovery sparked identification of numerous genes encoding
related proteins, termed orphan receptors. Characterization of these orphan receptors and, in
particular, of the retinoid X receptor (RXR) positioned nuclear receptors at the epicenter of the
‘‘Big Bang’’ of molecular endocrinology. This Review provides a personal perspective on nuclear
receptors and explores their integrated and coordinated signaling networks that are essential for
multicellular life, highlighting the RXR heterodimer and its associated ligands and transcriptional
mechanism.Introduction
The discovery of nuclear receptors has its historical roots in
endocrinology and the identification of the lipophilic hormones
that function as their ligands (Evans, 1988). Steroid and thyroid
hormones, along with vitamins A and D, were elucidated based
on their endocrine origin and the physiologic processes that
they regulate. Each of these small molecules is chemically
distinct, and although there was initially no presumption that
they might have a shared signaling mechanism, initial biochem-
ical experiments revealed the presence of an intracellular
receptor that, upon ligand addition, activated transcription of
tissue-specific sets of target genes (O’Malley, 1971; Yamamoto,
1985).
The idea of a ‘‘Nuclear Receptor’’ that could directly translate
simple chemical changes into distinct physiologic effects per-
sisted for several decades, but the fundamental nature of this re-
ceptor, its means for recognizing specific chemical ligands, its
mode of interactionwith the genome, and itsmechanism for con-
trol of gene transcription were all beyond the limits of classic
biochemical analysis. Subsequent investigation into the mecha-
nism of hormone action eventually led to the biochemical,
molecular, and genetic characterization of the genes encoding
the first steroid receptors in the mid-1980s (Mangelsdorf et al.,
1995).
The Dawn of a Superfamily
The isolation of the first complete steroid receptor cDNAs, the
glucocorticoid and estrogen receptors, was transformative
(Green et al., 1986; Hollenberg et al., 1985) (Figure 1). Compari-
son of the sequences revealed a conserved evolutionary tem-
plate, and it also permitted the delineation of the structural and
functional features that foreshadowed the emergence of a nu-
clear receptor superfamily. Each sequence harbors DNA bind-ing, ligand binding, and transactivation domains (Gigue`re et al.,
1986; Green et al., 1986; Miesfeld et al., 1986). Importantly,
access to the cDNAs enabled key experiments needed to test
protein function, includingmutagenesis of the receptor’s primary
structure to assess the importance of specific amino acids and
characterization of the nucleotide code within the target gene’s
promoter that allows gene-specific expression (Green and
Chambon, 1987; Umesono and Evans, 1989; Umesono et al.,
1988). As a result of this early work, transcriptional regulation
by hormone-receptor complexes was shown to be a funda-
mental process embedded in the circuitry of extracellular signal
transduction by lipophilic endocrine hormones and vitamins.
Perhaps the most revolutionary finding to come from the clon-
ing of the first steroid receptors was the surprising discovery that
dozens of other evolutionarily related proteins exist. Because
the associated small-molecule ligands were unknown, they
garnered the name ‘‘orphan’’ receptors (Giguere et al., 1988; Mil-
brandt, 1988; O’Malley, 1990; Wang et al., 1989). Of further phy-
logenic significance, these orphan receptors were shown to be
conserved throughout metazoan evolution, although it should
be noted that nuclear receptors are absent in protozoans, fungi,
and plants (Markov and Laudet, 2011; Owen and Zelent, 2000;
Robinson-Rechavi et al., 2004).
Engine of Discovery
That there were orphan receptors immediately suggested the
existence of a host of previously unknown signaling pathways
regulated by a myriad of undiscovered ligands. The question
was how might one go about discovering such ligands? The
answer came from a remarkable, innovative technological
achievement—the cotransfection assay (Gigue`re et al., 1986).
The idea went like this: if the cDNA encoding the receptor was
sufficient to reconstitute a hormone response, then expressionCell 157, March 27, 2014 ª2014 Elsevier Inc. 255
Figure 1. Nuclear Receptor Discovery Timeline
Schematic timeline showing landmark discoveries in the nuclear receptor field over the last three decades. The entries start from the cloning of the first steroid
hormone receptor cDNA to more recent ‘‘omic’’ findings. Inset on the right shows total publications for all nuclear receptors, as well as that for RXR and
heterodimer partners over time.plasmids harboring the receptor’s cDNA could be cotransfected
with a hormone-responsive reporter gene to create a highly
defined two-component regulatory switch. With the switch flip-
ped ‘‘on’’ by hormone binding, the resulting powerful transcrip-
tional response allowed rapid analysis of the receptor’s DNA
and ligand binding domains, as well as ligand and target gene
specificity. The cotransfection assay was so versatile as a cell-
based means to study transcription that it quickly became the
mainstay of virtually every molecular biology laboratory, as well
as a pharmaceutical discovery tool.
The cotransfection assay provided a quantitative and highly
efficient tool for screening, and as it was extremely sensitive to
small-molecule ligands, it became the mainstay of ‘‘deorphan-
ing’’ efforts. Early results showed that the DNA- and ligand-bind-
ing domains of the receptors function autonomously, which led
to the idea that one could swap these domains between recep-
tors, and even other transcription factors, and still retain ligand-
dependent transactivation (Giguere et al., 1987; Green and
Chambon, 1987; Petkovich et al., 1987). With the cDNAs of the
orphan receptors in hand, the cotransfection assay was instantly
adapted as an unbiased ligand screening method that could be
implemented even when the receptor’s DNA binding site (or
response element) was not precisely known (Chawla et al.,
2001). This ‘‘reverse endocrinology’’ concept allowed for high-
throughput screens of natural, synthetic, and xenobiotic ligands
that required less-than-micromolar concentrations to unearth256 Cell 157, March 27, 2014 ª2014 Elsevier Inc.which receptors might mediate their signaling (Kliewer et al.,
1999). In comparison, the classic endocrinology methods that
led to the isolation of thyroid hormone in 1914 required 3.5
tons of bovine thyroid gland (Kendall, 1917). Thus, the massive
shift in ligand screening sensitivity, as a consequence of receptor
cloning and powerful reporter assays, could now unveil new and
unimagined signaling systems.
RXR and the Big Bang
Applying the reverse endocrinology approach to the retinoid X
receptor (RXR) led to the identification of the first endogenous
ligand for an orphan nuclear receptor (9-cis retinoic acid, a
metabolite of vitamin A), establishing RXR as the founding mem-
ber of the ‘‘adopted’’ orphan class (Mangelsdorf et al., 1990;
Heyman et al., 1992; Levin et al., 1992) (see Table 1 for receptor
nomenclature for the entire superfamily). The discovery of RXR
and its ligand resulted in the genesis of two prodigious concepts
in the nuclear receptor field. First, in revealing the existence of a
previously unknown signaling pathway, it provided a proof of
principle that precipitated a wave of research aimed at linking
other orphan receptors to specific ligands.
Second, it led to the discovery of RXR heterodimerization with
these adopted orphan receptors, thereby defining a novel
feature of multiple intertwined signaling pathways (Figure 2).
For example, one of the first uses of the cotransfection
assay identified interactions between an orphan receptor and
compounds that promote peroxisome proliferation (fibrates and
nafenopin) as the first xenobiotic ligand-receptor pair. The then-
named peroxisome proliferator-activated receptor (PPAR) was
ultimately shown to be one of a family of fatty acid receptors
(Issemann and Green, 1990; Dreyer et al., 1992). PPARs were
the first class of orphan receptors shown to heterodimerize
with RXR (Kliewer et al., 1992).
We refer to the discovery of heterodimerization as the ‘‘RXR
Big Bang’’ because its explosive impact gave rise to a wave of
discovery, including entirely new physiologic signaling pathways
(Figure 2). The straightforward cotransfection assay yielded a
relatively familiar result—the receptor proteins are functional
heterodimers, and yet the complexity of regulation that has since
emerged, under both normal and pathological conditions, is
nothing short of astonishing.
What’s My Ligand?
Classic endocrinology identified thyroid hormone and vitamins A
and D as vital factors; however, these hormones bind their re-
ceptors with high affinity, similar to the classic steroid hormones.
In contrast, the reverse endocrinology strategy allowed for the
identification of lower-affinity endogenous ligands that were
derived from dietary lipids (Kliewer et al., 1999). Furthermore, a
major role of the receptors for these lipid-derived ligands was
to maintain the homeostasis of the ligands themselves. Thus,
the natural ligands being identified turned out to be predictive
hallmarks of the physiologic pathways being regulated by their
cognate receptors. For example, the finding that fatty acids are
endogenous ligands for PPARs led to the discovery that PPARs
govern fatty acid metabolism. Likewise, the binding of choles-
terol metabolites by LXR predicted its future role in controlling
cholesterol metabolism. This key bit of fortune, though in retro-
spect may appear obvious, was decidedly not so at the time.
Because the simple chemical structure of the ligand could fore-
tell the intrinsic function of the receptor, ligand discovery
became the clarion call of the field. Indeed, physiologic links
were quickly established in the growing list of orphan receptors
that were being adopted into the nuclear receptor superfamily.
These included fatty acid metabolism for the PPARs, sterol ho-
meostasis for the liver X receptors (LXRs), bile acid homeostasis
for the farnesoid X receptor (FXR), and endobiotic/xenobiotic
metabolism for pregnane X and constitutive androstane recep-
tors (PXR and CAR) (Chawla et al., 2001; O’Malley, 1990). Of
further import, these discoveries elaborated the existence of a
nuclear receptor superfamily and elucidated the unifying mech-
anism bywhich chemically diverse classes of hormones and bio-
logically active lipids coordinately regulate gene expression and
diverse physiological pathways.
Make It and Break It
A defining feature of hormone action is the dynamic synthesis
and subsequent degradation of receptor ligands. After all, this
feature is what drives the recurring nature of the signaling circuits
within the physiologic process. Ligand synthesis and its subse-
quent distribution deliver a body-wide hormonal response via
activation of receptor-mediated transcription, whereas ligand
degradation limits both duration and intensity of the response
by returning the system to its homeostatic baseline, where it isready for subsequent rounds of activation. For this cyclic pro-
cess to occur, the ligands themselves must first be produced
during the inductive phase and then eliminated to reset the bal-
ance. Thus, like the second law of thermodynamics, for every
physiologic action, there is an equal, but opposite reaction.
The unsung heroes in this dynamic process are the cyto-
chrome P450s (CYPs), whose unique ability to add molecular
oxygen to small molecules plays a key role in cholesterol, ste-
roid, and fatty acid metabolism (Baker, 2011; Zelko and Negishi,
2000). For example, all natural steroid hormones (glucocorti-
coids, mineralocorticoids, progesterone, estrogens, and andro-
gens) are synthesized from cholesterol in the gonads and
adrenal glands when CYP11A1 (in the mitochondria) converts
cholesterol to pregnenolone—the first reaction in steroidogene-
sis (Strushkevich et al., 2011; Hanukoglu, 1992). Several more
CYPs are specialized to advance pregnenolone metabolism to
the individual hormonal products. This unique relationship be-
tween steroid receptors and CYPs (as the ligand generators) ex-
tends to virtually all nuclear receptors with endogenous ligands.
Distinct CYPs play central roles in the production of vitamins A
and D for the RARs, RXRs, and VDR, as well for synthesis of oxy-
sterols for LXRs, bile acids for FXRs, and fatty acids and arach-
idonic acid for PPARs (Blumberg and Evans, 1998; Kliewer et al.,
1998; McSorley and Daly, 2000; Ray et al., 1997; Russell, 2009).
By virtue of their daily role in hormone synthesis, CYPs also
take center stage in receptor ligand inactivation and clearance,
a process mostly driven in the liver by the phase I, II, and III
response, which are controlled in large part by the xenobiotic re-
ceptors PXR and CAR. In addition to recognition of foreign com-
pounds (xenobiotics), these receptors also recognize and are
activated by endobiotic compounds: steroids, sterols, retinoids,
thyroid hormone, and bile acids (Kliewer et al., 1998; Blumberg
et al., 1998; Wei et al., 2000; Zelko and Negishi, 2000).
In understanding the unique evolution of nuclear receptors as
ligand-dependent transcription factors, it is of interest to note
that an important function of nuclear receptors is to autoregulate
their own activity by governing the transcription of the specific
CYPs that, in turn, control the concentration of their cognate
ligands. Examples of this regulatory circuit include the feedback
inhibition of steroid hormone synthesis via the hypothalamic pitu-
itary target organ axis (Dallman et al., 1994; Seminara and Crow-
ley, 2001), bile acid synthesis via the enterohepatic axis (de
Aguiar Vallim et al., 2013), and the feedforward regulation of oxy-
sterol, fatty acid, and vitamin D syntheses that are governed by
their respective receptors (Chawla et al., 2001;Ory, 2004). Taking
this regulatory circuit one step further, the ‘‘make it and break it’’
process uses a special class of orphan nuclear receptors,
including SF-1, DAX-1, LRH-1, and SHP, to sequentially produce
and eliminate ligands for receptors (PXR andCAR) so that the ho-
meostatic process can be maintained. Furthermore, given the
hydrophobic nature of nuclear receptor ligands, ligand transport
is coordinately regulated by the cognate receptor, including the
production of specific binding proteins and cellular transporters
(Pardridge, 1981; Watanabe et al., 1991).
The Heterodimer Rule
As transcription factors, nuclear receptors rely on DNA
sequence-specific binding to transactivate their target genes.Cell 157, March 27, 2014 ª2014 Elsevier Inc. 257
Table 1. Mammalian Nuclear Receptor Nomenclature and Ligands
Common Name
Common
Abbreviation
Unified
Nomenclature Ligands
Androgen receptor AR NR3C4 androgens
Constitutive androstane receptor CAR NR1I3 xenobiotics
Chicken ovalbumin upstream promoter-transcription factor a COUP-TFa NR2F1
Chicken ovalbumin upstream promoter-transcription factor b COUP-TFb NR2F2
Chicken ovalbumin upstream promoter-transcription factor g COUP-TFg NR2F6
Dosage-sensitive sex reversal-adrenal hypoplasia congenital
critical region on the X chromosome, gene 1
DAX-1 NR0B1
Estrogen receptor a ERa NR3A1 estrogens
Estrogen receptor b ERb NR3A2 estrogens
Estrogen related receptor a ERRa NR3B1
Estrogen related receptor b ERRb NR3B2
Estrogen related receptor g ERRg NR3B3
Farnesoid X receptor a FXRa NR1H4 bile acids
Farnesoid X receptor ba FXRb NR1H5
Germ cell nuclear factor GCNF NR6A1
Glucocorticoid receptor GR NR3CI glucocorticoids
Hepatocyte nuclear factor 4 a HNF4a NR2A1 [fatty acids]
Hepatocyte nuclear factor 4 g HNF4g NR2A2 [fatty acids]
Liver receptor homolog-1 LRH-1 NR5A2 [phospholipids]
Liver X receptor a LXRa NR1H3 oxysterols
Liver X receptor b LXRb NR1H2 oxysterols
Mineralocorticoid receptor MR NR3C2 mineralocorticoids and glucocorticoids
Nerve-growth-factor-induced gene B NGF1-B NR4A1
Neuron-derived orphan receptor 1 NOR-1 NR4A3
Nur-related factor 1 NURR1 NR4A2
Photoreceptor-cell-specific nuclear receptor PNR NR2E3
Peroxisome proliferator-activated receptor a PPARa NR1C1 fatty acids
Peroxisome proliferator-activated receptor b/d PPARb/d NR1C2 fatty acids
Peroxisome proliferator-activated receptor g PPARg NR1C3 fatty acids
Progesterone receptor PR NR3C3 progesterone
Pregnane X receptor PXR NR1I2 endobiotics and xenobiotics
Retinoic acid receptor a RARa NR1B1 retinoic acids
Retinoic acid receptor b RARb NR1B2 retinoic acids
Retinoic acid receptor g RARg NR1B3 retinoic acids
Reverse-Erb a REV-ERBa NR1D1 [heme]
Reverse-Erb b REV-ERBb NR1D2 [heme]
RAR-related orphan receptor a RORa NR1F1 [sterols]
RAR-related orphan receptor b RORb NR1F2 [sterols]
RAR-related orphan receptor g RORg NR1F3 [sterols]
Retinoid X receptor a RXRa NR2B1 9-cis retinoic acid and docosahexanoic acid
Retinoid X receptor b RXRb NR2B2 9-cis retinoic acid and docosahexanoic acid
Retinoid X receptor g RXRg NR2B3 9-cis retinoic acid and docosahexanoic acid
Steroidogenic factor 1 SF-1 NR5A1 [phospholipids]
Short heterodimeric partner SHP NR0B2
Tailless homolog orphan receptor TLX NR2E1
Testicular orphan receptor 2 TR2 NR2C1
Testicular orphan receptor 4 TR4 NR2C2
(Continued on next page)
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Table 1. Continued
Common Name
Common
Abbreviation
Unified
Nomenclature Ligands
Thyroid hormone receptor a TRa NR1A1 thyroid hormones
Thyroid hormone receptor b TRb NR1A2 thyroid hormones
Vitamin D receptor VDR NR1I1 1a,25-dihydroxyvitamin D3 and lithocholic acid
Ligands in brackets indicate atypical ligands that, by structural studies, appear to be constitutively bound to their receptors.
aFXRb exists only as a pseudogene in humans.Utilizing a combination of approaches that included the cotrans-
fection assay and the electrophoretic mobility shift assay, it was
determined that the classic steroid receptors (GR, PR, AR, and
ER) bind as homodimers to response elements configured as
palindromes composed of two hexad nucleotide sequences
separated by three base pairs (Beato, 1991).
In contrast, nonsteroid receptors (i.e., RAR, VDR, and TR),
bind preferentially to response elements composed of two
hexad half-sites arranged as tandem repeats (Koenig et al.,
1987; Na¨a¨r et al., 1991; Umesono et al., 1991). Further, the spec-
ificity of each of these receptor/DNA interactions was shown to
be encoded uniquely by the nucleotide spacing between the
two half-sites of the direct repeat. Thus, the response element
for vitamin D was shown to be a direct repeat spaced by three
nucleotides; for thyroid hormone, the spacing is four nucleo-
tides, and for retinoic acid, it is five nucleotides (an axiom that
became known as the 3-4-5 rule) (Figure 3) (Perlmann et al.,
1993; Umesono et al., 1991). However, perhaps themost striking
difference between these receptors and their steroid-binding,
homodimeric counterparts was that the nonsteroid receptors
bind DNA as part of a heterodimer in which their common partner
is RXR (Yu et al., 1991; Kliewer et al., 1992; Bugge et al., 1992;
Leid et al., 1992; Marks et al., 1992; Zhang et al., 1992). There
are now known to be three RXRs (RXRa, RXRb, and RXRg), at
least one of which is expressed in every cell in the body. The
three RXR proteins are highly conserved and functionally inter-
changeable both as heterodimer partners and as receptors for
9-cis retinoic acid (Mangelsdorf et al., 1992).
The paradigm of RXR heterodimerization quickly expanded
into the universe of orphan receptors that now included the
PPARs, LXRs, FXR, PXR, and CAR. The success of this para-
digm was due in large part because it provided a simple but
elegant solution to the evolution of target gene specificity. On
its own, RXR was shown to function as a self-sufficient homo-
dimer, binding to a direct repeat of half-sites separated by one
nucleotide (i.e., a DR1 element). The DR1 sequence was ideally
poised for evolution because it only required sequential intro-
duction of single nucleotides in the spacer between the two
DR1 half-sites to generate novel binding motifs (DR2, DR3,
DR4, etc.). A key driver of that process was the innate structure
of the RXR ligand binding domain that permits it to adoptmultiple
conformations and thereby dimerize with different nuclear re-
ceptors when bound to each of the direct repeat motifs (Rastine-
jad et al., 1995; Chandra et al., 2008; Lou et al., 2014). In this way,
each new heterodimer partner can bind to one of the half-sites,
whereas RXR can continue to occupy the other because of the
flexibility of its dimerization domain (Perlmann et al., 1993).This plasticity allowed the heterodimer rule to expand from the
prototypical 3-4-5 rule to include DR1 through DR5 response
elements selective for each RXR/receptor partner pair. Although
in nature RXR heterodimers have adapted the ability to bind
response elements that vary from the canonical direct repeats,
the veracity of the general rule has been confirmed by numerous
genome-wide binding analyses.
The crystal structures of the heterodimeric unit on DNA have
elucidated the molecular basis for these interactions (Rastinejad
et al., 1995; Chandra et al., 2008; Lou et al., 2014). The power of
the direct repeat rule is that it offered every heterodimer amolec-
ular binding target even in advance of knowledge of its regulatory
function. Even so, with five different binding sites (six if we
include the single inverted repeat for RXR/FXR), there are still
more heterodimers than binding sites. Thus, as would be ex-
pected, individual sites can be the target ofmultiple receptor het-
erodimers. This promiscuity adds a layer of complexity that may
be explained, in part, by tissue-specific expression of individual
receptor complexes or perhaps features in the chromatin envi-
ronment that help to ‘‘craft’’ specific binding environments.
Another interesting general property of the RXR heterodimer is
that, with only one or two special exceptions, the heterodimer
partners are all ligand dependent. Indeed, a curious evolutionary
oddity of the nuclear receptor superfamily has been the rather
surprising finding that not all of the orphans have ligands that
bind in a reversible, regulatory fashion. For those orphan recep-
tors in which such ligands have not been forthcoming, structural,
biochemical, and physiological evidence indicate that the ligand
binding pocket is either absent or occupied continually by a lipid
(Wisely et al., 2002), phospholipid (Krylova et al., 2005; Li et al.,
2005), or hydrophobic molecule such as heme (Raghuram
et al., 2007; Reinking et al., 2005; Yin et al., 2007). Consequently,
these orphan receptors generally behave as constitutive activa-
tors or repressors of transcription. With respect to their DNA
binding, they also function predominantly as monomers or
homodimers.
Of the 48 nuclear receptors in humans, approximately half of
them fall into the subclass lacking traditional ligands. This obser-
vation is of evolutionary interest, as this subclass comprises the
most ancient members of the nuclear receptor superfamily, and
homologs are found all the way down to the most primitive inver-
tebrate species. Notably, the only invertebrate species in which
ligand-dependent nuclear receptors have been discovered thus
far have been nematodes and arthropods. In C. elegans, for
example, only one out of 284 nuclear receptors has been charac-
terized as ligand dependent (Motola et al., 2006; Taubert et al.,
2011). In Drosophila, which has 21 nuclear receptors, only twoCell 157, March 27, 2014 ª2014 Elsevier Inc. 259
Figure 2. The RXR Big Bang
The cloning of the RXRs as receptors for 9-cis
retinoic acid initiated an expanding wave of dis-
coveries that included (1) the ability of RXRs to
heterodimerize with numerous other nuclear re-
ceptors as a mechanism to control gene-specific
transcription; (2) the characterization of dietary
lipid metabolites (i.e., oxysterols, bile acids, fatty
acids, and xenobiotic lipids) as ligands for
RXR-partnered orphan receptors; (3) the elucida-
tion of novel endocrine and paracrine signaling
pathways mediated by RXR heterodimers, in-
cluding the fibroblast growth factors 1, 19, 21, and
23; and (4) the role of these receptors in diverse
developmental and metabolic pathways. BMR,
basal metabolic rate.have been confirmed to have ligands (Fahrbach et al., 2012). One
of these is the ecdysteroid receptor, and it is of particular interest
because it functions as an obligate heterodimer with
ultraspiracle, the RXR homolog in insects (Oro et al., 1990; Yao
et al., 1992). Thus, the appearance of RXR heterodimerization
during evolution has been coincident with the dramatic expan-
sion of ligands for these receptors.
The Silent Partner
An inherent characteristic of the receptor heterodimer is its
potential to be activated by either the RXR ligand or the partner
receptor ligand. This structural reflection of dual-ligand regula-
tion can be divided into two categories: permissive and nonper-
missive heterodimers (Forman et al., 1995; Kurokawa et al.,
1993). Permissive heterodimers are those that can be activated
by ligands of either RXR or its partner, whereas nonpermissive
heterodimers are those that can only be activated by the
partner’s ligand while RXR is silent. An important regulatory
feature of permissive receptor partners (PPARs, LXRs, FXR,
PXR, and CAR) is that the simultaneous presence of both RXR
and partner receptor ligands results in a cooperative, synergistic
response compared to that resulting from binding of only a single
receptor ligand (Leblanc and Stunnenberg, 1995).
Dual-ligand regulation of permissive heterodimers can have
both physiologic and pharmacologic consequences. It is of
physiologic relevance that all of the permissive receptor partners
respond to dietary-derived lipids, whose levels can vary widely.
Yet, because of their synergistic relationship with the RXR ligand,
even relatively small changes in these lipids can result in robust
transcriptional activity and thus achieve a profound biological
response. Although endogenous RXR ligands have not been
confirmed in every tissue, it is conceivable that the presence of
even trace amounts of such ligands would enable a synergistic
response. With that in mind, it is of interest to note that, in addi-
tion to 9-cis retinoic acid, other tissue-specific RXR ligands (e.g.,
docosahexanoic acid in brain) have been identified (de Urquiza260 Cell 157, March 27, 2014 ª2014 Elsevier Inc.et al., 2000). From a pharmacologic
perspective, a number of potent synthetic
RXR ligands (called ‘‘rexinoids’’) have
also been described (Mukherjee et al.,
1997), and because of their ability to
simultaneously activate several hetero-dimers, such panagonists may have utility against multiple ther-
apeutic targets (Desvergne, 2007). Although the pharmacologic
importance of RXR as a therapeutic target is clear, proof of the
physiologic importance of endogenous RXR ligands awaits ex-
periments to effect genetic loss of ligand binding in both individ-
ual and combinations of each of the RXR isoforms.
In contrast to the lipid-sensing permissive partners, the
nonpermissive partners (e.g., TRs, VDR, and RARs) function pri-
marily as hormone receptors and have endocrine ligands that are
under tight regulatory control. By silencing RXR activity and re-
sponding only to their own ligands, these receptors permit tran-
scriptional regulation that is directly proportional to the level of
the hormone, thereby meeting the requirements of endocrine
physiology (Shulman and Mangelsdorf, 2005).
The Orphan Receptor Roadmap to Physiology: Engaging
the Energy Vector
Homeostasis is essentially a cooperative equilibrium among
cells, tissues, and organs that relies on a rigorous communica-
tion and sensory network as a means to sustain bodily function
in all metazoans. In contrast, bacteria and yeast effectively live
in their surrounding environment such that every cell must
compete for limiting nutrients. In this context, collective cell pro-
liferation usually continues until food sources are depleted and
there is no need for a ‘‘physiologic mechanism,’’ as all cells are
equal.
However, in metazoan physiology, cells, tissues, and organs
serve compartmentalized functions such that the internal envi-
ronment is distinct from the external environment—thus, the
organism must have dynamic, adaptive, and codependent
communication and metabolism at all times. Therefore, real-
time control over each metabolic pathway is an essential feature
of the homeostatic process. This modulation requires key regu-
latory sensors to be in place that can monitor levels of specific
metabolites and control rate-limiting nodes to reduce or enhance
specific routes of energy flux.
Figure 3. The 3-4-5 Rule
Receptors bind DNA asmonomers to a single hexadmotif, as homodimers to a
palindrome of two hexadmotifs, or as RXR heterodimers to a tandem repeat of
the hexad motif. Heterodimers bind AGGTCA direct repeats (DRs) spaced by
three (DR3; vitamin D response element), four (DR4; thyroid response element)
or five (DR5; retinoic acid response element) nucleotides as described in the
3-4-5 rule.The RXR-partnered receptors play a defining role in this pro-
cess. During the fed state, the body switches on a nuclear recep-
tor network that governs the uptake and storage of energy-rich
nutrients, as well as the protection from toxic dietary compo-
nents (Vacca et al., 2011). For example, in the intestine, FXR is
activated by sensing the postprandial increase in bile acids
that both facilitate absorption of lipids as well as activate a com-
plex gene expression program to help control diet-linked micro-
bial inflorescence and intestinal inflammation (de Aguiar Vallim
et al., 2013). This process serves to create an ‘‘energy vector’’
into the body while maintaining a barrier to the gut microbiome.
In part, FXR creates the energy vector by inducing nutrient trans-
porters to bring food into the body and by activating postprandial
liver metabolism, through the production of the intestinal hor-
mone FGF19, to help insulin build hepatic glycogen reserves
and to recycle and maintain proper bile acid levels (Potthoff
et al., 2012).
In concert with this process, activation of LXRs by dietary
cholesterol works together with insulin in the liver to promote
lipogenesis, further contributing to the energy vector by promot-
ing triglyceride production for delivery to peripheral tissues (Cal-
kin and Tontonoz, 2012). Activation of LXRs in both the gut and
the liver also serves to maintain whole-body cholesterol homeo-
stasis by upregulating a gene network that removes excess
cholesterol from the body through the process of reverse
cholesterol transport and hepatic catabolism of cholesterol
into bile acids. To ensure that proper bile acid homeostasis
and metabolic balance are maintained, activation of FXR in
the intestine and liver activates an important feedback loop to
turn off LXR, inhibit further bile acid synthesis, and reset the
digestive system once the meal is finished. The second tier of
this process is engaged in the periphery by the PPARs to either
consume or store excess nutrient lipids. In sensing the rising
levels of fatty acids via enhanced energy flux from the liver,
PPARa and PPARd are activated to manage triglyceride and
fatty acid metabolism by promoting mitochondrial b-oxidation
and ATP production in muscle and heart (de Lange et al.,
2008; Madrazo and Kelly, 2008). The excess energy not
consumed is captured and stored in adipose tissue under the
control of PPARg in conjunction with FGF21 and FGF1 to pro-
mote adipose remodeling (Dutchak et al., 2012; Jonker et al.,
2012; Tontonoz and Spiegelman, 2008). Thus, in a highly coop-
erative and integrated fashion, the intestine acquires nutrients,the liver transforms and delivers nutrients, and active tissues
burn nutrients, whereas adipose collects unused energy for
long-term storage without being a major consumer—effectively
representing an altruistic function.
Whereas the FXR/LXR/PPAR axis is on the front end of nutrient
acquisition, the xenobiotic receptors PXR and CAR are part of
the clearance system that allows the body to rid itself of toxic
dietary metabolites, drugs, and endobiotics (such as steroid,
retinoid, and thyroid hormones) (Willson and Kliewer, 2002).
The ability of these two receptors to be activated by hundreds
of compounds enables the transcription of a detoxification
gene program that creates a clearance vector through which
toxic body fluids are eliminated through the phase I, II, and III
arms of the xenobiotic response.
During privation, when nutrients are limiting or absent, the
entire energy vector is reversed, and the body now mobilizes
its stored energy reserves in adipose to use as fuel while at the
same time suppressing unnecessary energy consuming path-
ways. PPARa is a primary regulator of this adaptive response
to starvation, where, in the liver, it senses the reversed flux of
fatty acids and activates a gene network to convert fatty acids
into a usable energy source (i.e., ketone bodies) (Contreras
et al., 2013). Activation of PPARa also results in the production
of the hepatokine FGF21, which sends a stress signal to other
sites in the body, thereby facilitating the body’s adaptation to
an energy-deprived state (Potthoff et al., 2012).
Thus, unlike simple organisms in which the energy demands of
each member of the population are approximately equal, in
metazoans, such demands are highly variable. As direct sensors
of dietary lipids, bile acids, and their metabolites, RXR-partnered
receptors are key in controlling the dynamics of energy flow and
organ communication. This is summarized in Figure 4.
Novel Therapeutics on the ‘‘Event Horizon’’
An immediate implication that followed from the initial discovery
of the receptors for the steroid and thyroid hormones and vita-
mins A and D was their potential as therapeutic targets. Indeed,
drugs that target these receptors are among the most widely
used and commercially successful. Thus, it should not be sur-
prising that the RXRs and their orphan receptor partners might
become the next generation of relevant therapeutic targets.
Indeed, bexarotene and alitretinoin (RXRs), fibrates (PPARa),
and thiazolidinediones (PPARg) are already approved drugs for
treating cancer, hyperlipidemia, and type 2 diabetes, respec-
tively (Moore et al., 2006). Looking out on the ‘‘event horizon’’
of drug discovery, it is notable that FXR and LXR agonists are
in development for treating nonalcoholic steatohepatitis and
preventing atherosclerosis. Perhaps just as importantly, PXR
is now used routinely in the pharmaceutical industry to screen
all new drug candidates for potentially dangerous drug-drug
interactions.
Beyond the Big Bang
It is worth mentioning that another consequence of the RXR Big
Bang has been the discovery of several other orphan receptors
that integrate into the Ring of Physiology (Bookout et al., 2006;
Yang et al., 2006). The Nuclear Receptor Ring of Physiology is
a circular dendogram based on the unsupervised clustering ofCell 157, March 27, 2014 ª2014 Elsevier Inc. 261
Figure 4. Metabolic Homeostasis and the Energy Vector
The figure illustrates that nutrients, such as sugar and fat, enter the body and
are processed in a highly vectorial fashion. Vector 1: the gallbladder, pancreas,
and intestine are the most important digestive organs in the body. Detergent
properties of bile acids both solubilize lipids to promote lipid absorption and,
by activating FXR, to transiently induce hundreds of genes for nutrient trans-
port and suppression of microbial activity along with the release of FGF19 as a
hormonal signal to the liver. In the liver, PPARa is activated to break down fatty
acids and induce FGF21 as a hormonal signal to adipose (and other tissues in
the body). LXR induces Cyp7a1 to convert cholesterol into bile acid and
SREBP-1c activation for fatty acid synthesis. Vector 2: PPARd activation
during exercise triggers production of sugar and fat in the liver for delivery to
muscle for both glycolytic and oxidative metabolism. Vector 3: unconsumed
energy is sent to fat where, under the control of the PPARg-FGF1 and -FGF21
axis, nutrients are stored in adipose tissue. Vector 4: in response to demand,
nutrients stored in visceral fat are sent to muscle or other tissues.nuclear receptor mRNA expression in 39 mouse tissues that re-
vealed the relationship between nuclear receptor expression,
function, and physiology (Bookout et al., 2006).Many of these re-
ceptors, such as the RORs and Rev-Erbs that govern circadian
clocks (Guillaumond et al., 2005) and the ERRs that govern
energy homeostasis (Gigue`re, 2008), are notable for their coordi-
nate regulation of physiologic networks that often intersect with
the RXR heterodimers.
Genomic Gymnastics—Dynamic Physiology from
Dynamic Genomes
An unmet future goal of the nuclear receptor field and, indeed, of
transcription factors in general, is understanding how they
govern the transcriptional process. As ligand-dependent tran-
scription factors, nuclear receptors like the RXR heterodimers
must be understood as a consequence of their ability to interact
with the genome and promote chromatin remodeling that, via
epigenetic changes, in turn modulate gene expression. This pro-
cess must be dynamic, affecting elaborate networks of genes
and global patterns of gene expression. As this regulation is hor-
mone dependent, induction of this regulatory triad (DNA binding,
chromatin modulation, and transcriptional activation) must be
reversed when ligand levels recede. In essence, physiologic
complexity must arise from genomic complexity reflected by a
coordinated genome-wide interaction of the receptors with
DNA. One key to understanding this physiologic complexity
has come from the discovery of ‘‘pioneering factors’’ that func-
tion as tissue-specific transcriptional programmers. By helping
to guide cell lineage, pioneer factors set the genomic landscape
through which signal-dependent transcription factors can acti-262 Cell 157, March 27, 2014 ª2014 Elsevier Inc.vate target gene networks. Several studies have pointed to the
role pioneer factors play in collaborating with nuclear receptors
in a cell-type-specific manner (Heinz et al., 2010). In this way,
the same nuclear receptor is able to govern distinct transcrip-
tional networks in different cell types (Miranda et al., 2013).
Cistromes
In the past 20 years, we have learned that a major function of
RXR heterodimers is to act as a reversible switch, which, in the
absence of ligand, recruits a complex of factors (i.e., corepres-
sors) to target gene promoters to repress transcriptional output,
whereas, in the presence of the ligand, the heterodimer recruits
coactivator complexes to open up chromatin and turn up tran-
scription of target genes (O’Malley et al., 2012; Rosenfeld
et al., 2006). This view, although still largely correct, is only one
layer of the complexity of the process. To understand the
complete logic of how these receptors function, one needs to
transition from probing single DNA-binding elements near the
promoter to surveying chromatin interactions at the genome-
wide scale. The development of high-throughput techniques to
analyze these receptor-DNA interactions (e.g., chromatin immu-
noprecipitation sequencing, ChIP-seq) has not only confirmed
the structure-function rules for nuclear receptor response ele-
ments but has also led to a number of unexpected results. A
rather surprising finding is that the sum total of individual binding
sites (cumulatively called a cistrome) for a single receptor in a
typical cell may comprise 10,000–25,000 sites within 250–
1,000 genes (Tang et al., 2011). What do these many thousands
of binding events tell us about hormone signaling? Are they all
important, and if not, is there a way to decipher those that are
functional from those that are inactive decoys?Minimally, cistro-
mic analysis is valuable as it allows the positioning of RXR-heter-
odimers in relation to specific genes. Unlike steroid receptors
that enter the nucleus with ligand treatment, RXR heterodimers
remain nuclear (and bound to many of these sites) whether acti-
vated by ligand or not. In this context, RXR heterodimers are
unusual in the sense that a single bound factor at a single site
can cycle as both a positive and negative regulator, depending
on the presence or absence of a ligand. An interesting general
feature from cistromes is that motif analysis can only confirm
binding to known sites. Thus, divergent DNA binding elements
may be present, but difficult to identify. In addition, as at least
1/3 or more binding events have no clear hormone response
element; perhaps this fraction of chromatin bound nuclear re-
ceptors is present due to direct recruitment to other transcription
factors (tethering).
Although cistromic analysis can uncover multiple cooperative,
interactive, and synergistic relationships, it still represents only a
‘‘snapshot’’ of a very dynamic and possibly short-lived process.
Though fragmentary, significant evidence is accumulating that,
in any one cell type, cistromes can expand and contract depend-
ing on developmental or environmental signals that trigger
expression or influx of transcription factors such as FOXa1
NF-kB, SMADs, and STATs into the nucleus. This process clearly
can expose large numbers of cryptic nuclear receptor binding
elements. As just one example, in hepatic stellate cells, RXR/
VDR heterodimers bind 6,281 sites in quiescent cells and
24,984 sites following LPS and TGFb-activation (Ding et al.,
2013). What triggers movement of RXR/VDR to new sites is not
known but seems to be important as it allows nuclear receptors
to be recruited to regions of genomic activity, even if these are
only transient in nature. The ability to move ensures that hor-
mone-responsive gene regulation can participate in the control
of all key gene networks in real-time as these networks are them-
selves being formed. Thus, the mechanism of ‘‘motional adapt-
ability’’ is important to explore as it underpins the rapid and
dynamic features of hormone signaling.
Enhancers and Transcriptomes
Although cistromes can be dynamic, they are still a type of
‘‘genographical’’ homing mechanism that needs to be placed
in context of the enhancer. Enhancers represent the clustering
of cis-regulatory elements that can confer both positive and
negative regulation on target genes. In general, the average dis-
tance of an enhancer from a promoter is 100 kb, greatly
strengthening the idea that the enhancer functions, in part, via
DNA looping with the regulated promoter (Sanyal et al., 2012).
Whether loops themselves are hormone inducible has not been
established, and whether hormone repression involves loop
disruption needs to be addressed.
New techniques such as global run-on sequencing (GRO-seq)
canmeasure near-instantaneous changes in expression in a sen-
sitive and quantitative fashion. GRO-seq analysis unexpectedly
revealed that upstreamenhancers produce short noncoding tran-
scripts known as eRNAs (Hah and Kraus, 2014). Recent work
(Lamet al., 2013) supports the idea that orphan nuclear receptors
can dial up or down the transcriptional output of the eRNA in a
fashion linked to the transcriptional activity of the downstream
gene itself (Hah et al., 2011). Although this is still very early days,
the idea that eRNAs are ligand responsive leads us to wonder
whether enhancer transcripts represent the initial level of hormon-
al control of gene expression. Addressing this important question
will undoubtedly comprise a major feature of future analysis.
One other class of specialty components of the transcriptome
that deserves mention is the microRNAs, which, by virtue of hy-
bridizing with a complementary sequence, repress gene expres-
sion. Their relationship to RXR-heterodimer signaling is just now
coming to light. For example, in the case of muscle thyroid hor-
mone signaling, expression of a single miRNA represses type I
myofiber formation to produce a fast muscle phenotype. Thus,
via their receptor-mediated expression, miRNAs can silence
large networks of genes and thereby play a key role in mediating
the hormonal response (Gan et al., 2013; van Rooij et al., 2007;
Williams et al., 2009). Future studies are needed to catalog and
characterize nuclear receptor-regulated miRNAs and their
contribution to both tissue and systemic physiology.
Although genome-wide DNA sequencing technology helped
to create a map of coding sequences, introns, and regulatory
sites, sequence information by itself is static. What we are
learning is that, although there is only one genome in a person,
there will be many ‘‘epigenomes’’ throughout the body and
that, even in small clusters of cells, such epigenomes may be
dynamic. This epigenetic interface is nowwhere a deeper under-
standing of nuclear receptor-regulated complex physiologic pro-
cesses will begin to emerge.
Expanding the Nuclear Receptor Universe
Progress in molecular biology, genetics, chemistry, and struc-
ture has led to a vast accumulation of knowledge about theidentities, regulation, and function of RXR and its heterodimeric
partners since their original discovery more than 25 years ago.
Much of this progress has been facilitated by striking advances
in physiological techniques and model in vivo systems, as well
as in ‘‘omic’’ technologies. As these technologies have
continued to advance, so have the critical informatic methods
to interrogate and compare the massive data being generated.
Yet, although much has been learned about each of the adopted
orphan RXR partners, it seems we have only begun to scratch
the surface on a true understanding of their physiologic func-
tions. The challenge represents a computational window into
the complexity of the physiologic process itself.
Conclusions
By takinga stepback, in this perspective,wehave tried toprovide
a broad overview of the cumulative progress in understanding
nuclear receptor function in classic endocrinology and, more
importantly, to chart the expanding impact of the RXR ‘‘Big
Bang’’ on new biology. Physiology reflects integrated body-
wide processes with receptors, metabolites, ligand, and conjoint
signalingmolecules in a continual orchestration,muchofwhich is
involved in the ‘‘trafficking’’ of nutrients throughout the body,
along with hormonal signals that open and close portals to tis-
sues, organs, and cells. Althoughmany of these events are trace-
able in blood, amore complete understandingwill require amuch
deeper insight into thebrain as a specialized endocrine organand
into how it oversees what we now call physiologic integration.
Nevertheless, great advanceshavebeenmade and remarkable
insights gleaned intodozensof newphysiologic pathways, aswell
as into pathology and treatment throughmodulation of nuclear re-
ceptor function. Orphan nuclear receptors have now transitioned
through the tipping point as therapeutic targets in the treatment
of human disease. Thus, the ‘‘Big Bang’’ is still expanding,
enhancing our insight into a modern definition of physiology with
unlimited potential to uncover the secrets of the human condition.
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